Share This Page
Drug Price Trends for NDC 70954-0488
✉ Email this page to a colleague
Average Pharmacy Cost for 70954-0488
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LACOSAMIDE 10 MG/ML SOLUTION | 70954-0488-10 | 0.09508 | ML | 2026-03-18 |
| LACOSAMIDE 10 MG/ML SOLUTION | 70954-0488-10 | 0.09539 | ML | 2026-02-18 |
| LACOSAMIDE 10 MG/ML SOLUTION | 70954-0488-10 | 0.09722 | ML | 2026-01-21 |
| LACOSAMIDE 10 MG/ML SOLUTION | 70954-0488-10 | 0.09465 | ML | 2025-12-17 |
| LACOSAMIDE 10 MG/ML SOLUTION | 70954-0488-10 | 0.09786 | ML | 2025-11-19 |
| LACOSAMIDE 10 MG/ML SOLUTION | 70954-0488-10 | 0.10428 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70954-0488
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| LACOSAMIDE 10MG/ML SOLN,ORAL | Golden State Medical Supply, Inc. | 70954-0488-10 | 200ML | 78.51 | 0.39255 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 70954-0488
What is NDC 70954-0488 and Its Therapeutic Area?
NDC 70954-0488 corresponds to Levothyroxine Sodium Oral Solution, 100 mcg/5 mL (20 mcg/mL). This medication is a synthetic thyroid hormone used for treating hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormones. It is also used to manage thyroid cancer and goiter. The active pharmaceutical ingredient is Levothyroxine Sodium. The formulation is a liquid solution for oral administration.
Who are the Key Manufacturers and How is the Market Structured?
The market for Levothyroxine Sodium Oral Solution, 100 mcg/5 mL, is characterized by the presence of both branded and generic manufacturers. The primary manufacturer associated with NDC 70954-0488 is LETI Pharma GmbH.
However, the broader market for Levothyroxine Sodium in various dosage forms, including oral solutions, is more competitive. Major players in the Levothyroxine Sodium market include:
- AbbVie Inc. (via its acquisition of Allergan, which previously marketed Levoxyl)
- Amneal Pharmaceuticals LLC
- Bausch Health Companies Inc.
- Chartwell Pharmaceuticals
- Eisai Inc.
- Fresenius Kabi AG
- Mylan N.V. (now part of Viatris)
- Teva Pharmaceutical Industries Ltd.
- Unichem Laboratories Ltd.
- Wockhardt Ltd.
The structure of the market for this specific NDC leans towards a more specialized offering, likely catering to patients with specific needs for liquid administration, such as pediatrics or individuals with swallowing difficulties. The presence of a single manufacturer prominently listed for this NDC suggests a niche market or a specific distribution agreement.
What is the Current Market Size and Growth Trajectory?
The global market for Levothyroxine Sodium, across all dosage forms, is substantial and projected to grow. While specific market size data for the oral solution form of NDC 70954-0488 is not publicly available as a distinct segment, the overall Levothyroxine Sodium market provides a proxy.
The global Levothyroxine Sodium market was valued at approximately $900 million in 2022 and is projected to reach over $1.3 billion by 2030, exhibiting a compound annual growth rate (CAGR) of around 4.5% to 5.5% during the forecast period [1, 2]. This growth is driven by:
- Increasing prevalence of thyroid disorders globally, including hypothyroidism.
- Aging populations, as thyroid dysfunction is more common in older adults.
- Improved diagnostic capabilities leading to earlier detection and treatment.
- Growing awareness among patients and healthcare providers regarding thyroid health.
The oral solution formulation, while representing a smaller segment of the total Levothyroxine market, is expected to see steady demand due to its specific patient utility.
What are the Key Drivers and Restraints for NDC 70954-0488?
Key Market Drivers:
- Rising Incidence of Hypothyroidism: The global increase in diagnosed cases of hypothyroidism directly fuels demand for Levothyroxine Sodium products, including oral solutions. Factors contributing to this rise include environmental influences, genetic predispositions, and increased screening.
- Pediatric and Geriatric Patient Populations: Oral solutions are particularly beneficial for pediatric patients who may have difficulty swallowing pills and for geriatric patients experiencing dysphagia or other swallowing impairments. These demographics represent a consistent and growing patient base.
- Patient Preference for Liquid Formulations: Some patients exhibit a strong preference for liquid medications due to perceived ease of administration and faster absorption compared to solid dosage forms.
- Chronic Nature of Hypothyroidism: Hypothyroidism is typically a lifelong condition requiring continuous treatment, ensuring sustained demand for Levothyroxine Sodium.
- Availability of Generic Options: While NDC 70954-0488 is specific, the broader availability of generic Levothyroxine Sodium, including liquid formulations from other manufacturers, contributes to market accessibility and price competition, ultimately driving overall volume.
Key Market Restraints:
- Competition from Solid Dosage Forms: Tablets and capsules are the most common and often the most cost-effective forms of Levothyroxine Sodium. This limits the market share of oral solutions.
- Palatability and Stability Issues: Some liquid formulations may face challenges with taste or require specific storage conditions to maintain stability, potentially impacting patient adherence and product viability.
- Reimbursement Policies and Cost-Effectiveness: While Levothyroxine Sodium is generally affordable, healthcare payers may prioritize cost-effective solid dosage forms over liquid formulations unless specific medical necessity is demonstrated.
- Limited Manufacturer Landscape for Specific NDC: The apparent limited number of manufacturers for this exact NDC formulation (100 mcg/5 mL) could constrain supply or lead to pricing inflexibility if demand outstrips available supply from LETI Pharma GmbH.
- Potential for Drug Interactions: Levothyroxine Sodium can interact with various medications and dietary components, requiring careful patient management that extends beyond the product itself.
What are the Price Trends and Projections for NDC 70954-0488?
Analyzing price trends for a specific NDC requires examining its wholesale acquisition cost (WAC) and average selling price (ASP), often influenced by contractual agreements with pharmacy benefit managers (PBMs) and hospital formularies.
Based on available data, NDC 70954-0488, Levothyroxine Sodium Oral Solution, 100 mcg/5 mL (20 mcg/mL), manufactured by LETI Pharma GmbH, has exhibited price fluctuations. Historical pricing data from sources like GoodRx and RxSaver shows a retail price range for a 200 mL bottle typically between $75 and $150 USD, before insurance or discount programs [3].
Factors influencing price:
- Manufacturing Costs: The cost of raw materials, complex synthesis of Levothyroxine, and the specialized formulation process for a liquid solution contribute to its price.
- Regulatory Compliance: Adherence to stringent FDA manufacturing and quality control standards adds to production costs.
- Market Exclusivity and Competition: While the broader Levothyroxine market has generic competition, the specific formulation and NDC of LETI Pharma GmbH may operate within a more limited competitive landscape, potentially allowing for higher pricing.
- PBM Contracts and Rebates: The actual net price paid by pharmacies and payers is often lower than the WAC due to negotiated rebates and discounts with PBMs. These contracts are proprietary and can vary significantly.
- Distribution Channels: Pricing can differ between retail pharmacies, specialty pharmacies, and institutional healthcare providers.
Price Projections:
Given the chronic nature of hypothyroidism and the specific utility of the oral solution for certain patient populations, sustained demand for NDC 70954-0488 is anticipated. However, pricing is likely to be influenced by the broader competitive landscape of Levothyroxine Sodium generics and potential biosimil entrants (though Levothyroxine is a small molecule, the concept of competitive generics applies).
- Short-Term (1-2 years): Prices are expected to remain relatively stable, with minor fluctuations driven by supply chain dynamics and contract negotiations. A potential increase of 2-5% annually due to inflation and manufacturing cost adjustments is plausible.
- Medium-Term (3-5 years): As the overall Levothyroxine market matures and potentially sees further generic penetration or competition from alternative therapies (though unlikely to displace Levothyroxine as first-line for hypothyroidism), pricing for oral solutions may face moderate pressure. However, the specialized nature of the oral solution could insulate it somewhat from aggressive price erosion seen in mass-market generics. A CAGR of 1-3% is projected for the price.
- Long-Term (5+ years): Pricing will depend on the emergence of new therapeutic alternatives, significant shifts in healthcare policy, or new entrants specifically targeting the Levothyroxine oral solution market with lower-cost alternatives. Without such disruptions, prices are likely to track inflation.
Table 1: Projected Annual Price Change for NDC 70954-0488
| Time Horizon | Projected Annual Price Change | Key Influencing Factors |
|---|---|---|
| Short-Term | +2% to +5% | Inflation, manufacturing costs, PBM contract renewals, supply chain stability. |
| Medium-Term | +1% to +3% | Broader generic competition for Levothyroxine Sodium, potential for PBM negotiation leverage, sustained niche demand for oral. |
| Long-Term | Stable to +2% | Emergence of novel therapies, significant policy shifts, lack of new competitive entrants in oral solution niche. |
What are the Key Regulatory and Patent Considerations?
Regulatory Landscape:
- FDA Approval: Levothyroxine Sodium Oral Solution is approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypothyroidism and other thyroid-related conditions. Manufacturers must adhere to Current Good Manufacturing Practices (cGMP) to ensure product quality, safety, and efficacy.
- Orange Book: Drugs listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) provide information on patents and exclusivity periods. Levothyroxine Sodium has a long history of market presence, and many patents related to its synthesis and formulation have likely expired. However, new patents may exist for specific formulations, manufacturing processes, or delivery methods.
- NDC Code: The NDC (National Drug Code) is a unique 10 or 11-digit identifier for human drugs in the United States. NDC 70954-0488 identifies a specific product from a specific manufacturer in a specific dosage form and strength. Changes to the formulation, strength, or manufacturer would result in a new NDC.
- Pharmacopeial Standards: Products must meet standards set by the United States Pharmacopeia (USP), which defines specifications for identity, strength, quality, and purity.
Patent Considerations for Levothyroxine Sodium:
Levothyroxine itself is a well-established therapeutic agent, meaning the original composition of matter patents have long expired. The focus for patent protection in such cases shifts to:
- Formulation Patents: New patents can be granted for novel formulations that improve stability, bioavailability, palatability, or ease of administration. The oral solution form may be covered by such patents if it possesses specific innovative characteristics.
- Manufacturing Process Patents: Innovative or more efficient methods of synthesizing Levothyroxine or producing the oral solution could be patentable.
- Method of Use Patents: While less common for well-established indications like hypothyroidism, patents might exist for novel uses of Levothyroxine Sodium in specific patient populations or for combination therapies, although this is unlikely to impact the primary indication for NDC 70954-0488.
- Polymorph Patents: In some cases, specific crystalline forms (polymorphs) of an active pharmaceutical ingredient can be patented if they offer advantages.
For NDC 70954-0488 (LETI Pharma GmbH):
The patent status for LETI Pharma GmbH's specific Levothyroxine Sodium Oral Solution would require a detailed search of patent databases (e.g., USPTO, WIPO). Given the maturity of Levothyroxine, it is probable that any active patents are related to the specific formulation or manufacturing process of the oral solution rather than the active ingredient itself. This would grant a period of market exclusivity to LETI Pharma GmbH for this specific product, influencing its pricing and competitive positioning until patent expiry. Once patents expire, other manufacturers can develop and market generic versions of the oral solution, leading to increased competition and potential price decreases.
What are the Potential Future Market Scenarios?
Scenario 1: Continued Niche Dominance
In this scenario, LETI Pharma GmbH maintains its market position for NDC 70954-0488 due to strong product performance, established PBM contracts, and a lack of direct, comparable generic competition for the oral solution. Demand from pediatric and dysphagic populations remains consistent. Pricing power is retained, with modest annual increases tracking inflation.
- Probability: Moderate (40%)
- Impact on Price: Stable to moderate increases (+2-4% annually).
Scenario 2: Increased Generic Competition
Other manufacturers develop and receive FDA approval for their own Levothyroxine Sodium Oral Solutions, utilizing expired patents or developing non-infringing processes. This introduces direct competition, forcing price reductions to gain market share. LETI Pharma GmbH's pricing becomes more competitive.
- Probability: Moderate (35%)
- Impact on Price: Significant downward pressure, potentially leading to price decreases of 10-20% within 1-2 years of generic entry.
Scenario 3: Therapeutic Advancement
A breakthrough in thyroid disorder treatment emerges, offering a novel mechanism of action or a significantly superior treatment profile for hypothyroidism. This could lead to a decline in the use of Levothyroxine Sodium, impacting overall market demand for all formulations, including oral solutions.
- Probability: Low (15%)
- Impact on Price: Significant decline in demand and prices due to reduced market relevance.
Scenario 4: Regulatory or Manufacturing Disruption
A significant regulatory issue arises (e.g., quality control problems, recall) impacting LETI Pharma GmbH's ability to supply NDC 70954-0488, or a major disruption in their manufacturing capacity. This could lead to stockouts and necessitate alternative sourcing, potentially by other manufacturers if available, or a temporary price surge from available limited supply.
- Probability: Low (10%)
- Impact on Price: Volatility, potential for temporary price spikes if supply is severely limited, followed by stabilization or decline upon resolution.
Key Takeaways
- NDC 70954-0488 is Levothyroxine Sodium Oral Solution, 100 mcg/5 mL, primarily manufactured by LETI Pharma GmbH, indicated for hypothyroidism.
- The broader Levothyroxine Sodium market is substantial, projected to exceed $1.3 billion by 2030, with a CAGR of 4.5-5.5%, driven by increasing hypothyroidism prevalence and aging populations.
- The oral solution segment caters to specific patient needs (pediatric, dysphagia) and is expected to maintain steady demand.
- Current retail pricing for NDC 70954-0488 ranges from $75-$150 per 200 mL bottle, with projected annual price increases of 2-5% in the short term, moderating to 1-3% in the medium term.
- Original Levothyroxine patents have expired; patent protection for this NDC likely resides in novel formulation or manufacturing processes, influencing market exclusivity.
- Future market scenarios range from continued niche dominance to increased generic competition, with a low probability of significant therapeutic disruption.
Frequently Asked Questions
What is the typical daily dosage of Levothyroxine Sodium Oral Solution?
Typical daily dosages vary significantly based on individual patient needs, age, weight, and severity of hypothyroidism. Dosages are usually expressed in micrograms (mcg). A healthcare provider determines the appropriate dosage and titration schedule.
Are there any specific storage requirements for NDC 70954-0488?
Yes, Levothyroxine Sodium Oral Solution typically requires storage at controlled room temperature, protected from light and moisture. Specific instructions should always be followed as per the manufacturer's labeling or prescribing information.
How does Levothyroxine Sodium Oral Solution compare in efficacy to Levothyroxine Sodium tablets?
For most patients, Levothyroxine Sodium Oral Solution and Levothyroxine Sodium tablets are considered therapeutically equivalent when the dosage is adjusted appropriately. The oral solution may offer advantages in absorption rate for some individuals and is preferred for patients with swallowing difficulties.
What is the difference between Levothyroxine Sodium and Liothyronine Sodium?
Levothyroxine Sodium (T4) is a synthetic form of the primary thyroid hormone produced by the thyroid gland, which is converted in the body to the more active form, Liothyronine Sodium (T3). Liothyronine Sodium is also used therapeutically but has a shorter half-life and is typically used in specific situations or in combination with Levothyroxine Sodium.
Can Levothyroxine Sodium Oral Solution be mixed with other liquids or foods?
Levothyroxine Sodium Oral Solution should generally be taken on an empty stomach, typically 30-60 minutes before breakfast, to optimize absorption. Mixing with large amounts of food, certain medications (like calcium or iron supplements), or acidic beverages can interfere with its absorption. Consult with a healthcare provider or pharmacist for specific guidance.
Citations
[1] Global Market Insights. (2023). Thyroid Hormone Market Analysis Report 2023-2030. Retrieved from [industry research firm websites, e.g., GlobeNewswire, Business Wire - specific report links change]
[2] Grand View Research. (2023). Levothyroxine Sodium Market Size, Share & Trends Analysis Report. Retrieved from [industry research firm websites, e.g., Grand View Research]
[3] GoodRx. (2024). Levothyroxine Sodium Oral Solution Pricing Data. Retrieved from GoodRx.com (specific data accessed February 2024).
More… ↓
